News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
641,064 Results
Type
Article (49126)
Company Profile (231)
Press Release (591694)
Multimedia
Podcasts (156)
Webinars (25)
Section
Business (177773)
Career Advice (2602)
Deals (32738)
Drug Delivery (134)
Drug Development (79396)
Employer Resources (169)
FDA (16531)
Job Trends (13736)
News (315148)
Policy (32733)
Tag
Academia (2434)
Academic (1)
Accelerated approval (18)
Adcomms (35)
Allergies (118)
Alliances (45034)
ALS (141)
Alzheimer's disease (1638)
Antibody-drug conjugate (ADC) (252)
Approvals (16561)
Artificial intelligence (432)
Autoimmune disease (92)
Automation (22)
Bankruptcy (330)
Best Places to Work (10192)
BIOSECURE Act (23)
Biosimilars (166)
Biotechnology (114)
Bladder cancer (133)
Brain cancer (47)
Breast cancer (485)
Cancer (3822)
Cardiovascular disease (328)
Career advice (2187)
Career pathing (38)
CAR-T (220)
CDC (57)
Cell therapy (624)
Cervical cancer (30)
Clinical research (66686)
Collaboration (1286)
Company closure (4)
Compensation (934)
Complete response letters (60)
COVID-19 (2761)
CRISPR (72)
C-suite (559)
Cystic fibrosis (129)
Data (4541)
Decentralized trials (2)
Denatured (45)
Depression (108)
Diabetes (424)
Diagnostics (5814)
Digital health (31)
Diversity (11)
Diversity, equity & inclusion (43)
Drug discovery (195)
Drug pricing (192)
Drug shortages (35)
Duchenne muscular dystrophy (200)
Earnings (72861)
Editorial (55)
Employer branding (20)
Employer resources (151)
Events (98326)
Executive appointments (913)
FDA (19008)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (12)
Funding (1119)
Gene editing (155)
Generative AI (37)
Gene therapy (511)
GLP-1 (1000)
Government (4298)
Grass and pollen (8)
Guidances (364)
Healthcare (16081)
HIV (46)
Huntington's disease (40)
IgA nephropathy (64)
Immunology and inflammation (246)
Immuno-oncology (22)
Indications (57)
Infectious disease (2990)
Inflammatory bowel disease (179)
Inflation Reduction Act (14)
Influenza (91)
Intellectual property (187)
Interviews (479)
IPO (15479)
IRA (57)
Job creations (3874)
Job search strategy (1813)
Kidney cancer (16)
Labor market (74)
Layoffs (612)
Leadership (37)
Legal (7921)
Liver cancer (87)
Longevity (12)
Lung cancer (554)
Lymphoma (258)
Machine learning (29)
Management (59)
Manufacturing (614)
MASH (141)
Medical device (11823)
Medtech (11844)
Mergers & acquisitions (18134)
Metabolic disorders (1131)
Multiple sclerosis (138)
NASH (23)
Neurodegenerative disease (214)
Neuropsychiatric disorders (61)
Neuroscience (2645)
NextGen: Class of 2025 (5536)
Non-profit (3449)
Now hiring (49)
Obesity (561)
Opinion (300)
Ovarian cancer (125)
Pain (161)
Pancreatic cancer (164)
Parkinson's disease (237)
Partnered (24)
Patents (407)
Patient recruitment (314)
Peanut (52)
People (53461)
Pharmaceutical (90)
Pharmacy benefit managers (29)
Phase I (20544)
Phase II (28951)
Phase III (22577)
Pipeline (2721)
Policy (298)
Postmarket research (2611)
Preclinical (8399)
Press Release (50)
Prostate cancer (198)
Psychedelics (51)
Radiopharmaceuticals (256)
Rare diseases (665)
Real estate (5437)
Recruiting (69)
Regulatory (24099)
Reports (42)
Research institute (2261)
Resumes & cover letters (428)
Rett syndrome (15)
RNA editing (13)
RSV (68)
Schizophrenia (137)
Series A (193)
Series B (142)
Service/supplier (14)
Sickle cell disease (78)
Special edition (26)
Spinal muscular atrophy (158)
Sponsored (40)
Startups (3363)
State (2)
Stomach cancer (17)
Supply chain (99)
Tariffs (96)
The Weekly (109)
Vaccines (1016)
Venture capital (66)
Weight loss (401)
Women's health (49)
Worklife (21)
Date
Last 7 days (741)
Last 30 days (2500)
Last 365 days (30290)
2025 (25251)
2024 (33902)
2023 (37955)
2022 (48576)
2021 (52355)
2020 (49729)
2019 (40557)
2018 (30959)
2017 (31273)
2016 (30064)
2015 (33726)
2014 (27398)
2013 (23039)
2012 (24702)
2011 (25296)
2010 (23250)
Location
Africa (796)
Alabama (63)
Alaska (7)
Arizona (219)
Arkansas (12)
Asia (39863)
Australia (6413)
California (8977)
Canada (2517)
China (861)
Colorado (375)
Connecticut (410)
Delaware (265)
Europe (90332)
Florida (1359)
Georgia (274)
Hawaii (3)
Idaho (46)
Illinois (667)
India (50)
Indiana (401)
Iowa (18)
Japan (324)
Kansas (105)
Kentucky (32)
Louisiana (15)
Maine (71)
Maryland (1201)
Massachusetts (6686)
Michigan (239)
Minnesota (501)
Mississippi (3)
Missouri (99)
Montana (19)
Nebraska (22)
Nevada (100)
New Hampshire (62)
New Jersey (2532)
New Mexico (26)
New York (2405)
North Carolina (1254)
North Dakota (7)
Northern California (4213)
Ohio (248)
Oklahoma (16)
Oregon (34)
Pennsylvania (1830)
Puerto Rico (17)
Rhode Island (34)
South America (1166)
South Carolina (47)
South Dakota (1)
Southern California (3469)
Tennessee (136)
Texas (1338)
United States (32419)
Utah (232)
Virginia (226)
Washington D.C. (77)
Washington State (739)
West Virginia (4)
Wisconsin (83)
Wyoming (1)
641,064 Results for "ascendis pharma a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare Diseases
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause
Therapies from industry leaders BioMarin and Ascendis Pharma supply a key hormone that promotes bone growth. In order to move the field forward, challengers are looking to address the underlying cause of the rare, genetic disease.
October 13, 2025
·
7 min read
·
Tristan Manalac
Press Releases
Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference
August 28, 2025
·
3 min read
Editorial
GSK CEO Emma Walmsley’s Departure Reseals Pharma’s Glass Ceiling
After Emma Walmsley steps down as GSK CEO in January, Vertex Pharma’s Reshma Kewalramani will be the sole female CEO at a top-20 pharma company. Still, there are many prominent women in pharma that could someday break through again.
September 29, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Ascendis Pharma Reports Second Quarter 2025 Financial Results
August 8, 2025
·
12 min read
Government
How the UK’s ‘Credibility Challenge’ Hinders Attempts To Reverse Pharma’s Flight
Talks between pharma and successive U.K. governments have failed to deliver the market access terms that the industry wants, contributing to a pullback in investment.
October 1, 2025
·
4 min read
·
Nick Paul Taylor
Press Releases
Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
July 31, 2025
·
3 min read
Metabolic disorders
Ascendis Skids as FDA Detects Death in Patient Formerly on Yorvipath
The death occurred in a patient who had a complex medical background and who was being managed with several drugs, according to RBC Capital.
October 21, 2025
·
2 min read
·
Tristan Manalac
C-suite
GSK’s Emma Walmsley, Pharma’s First Woman CEO, Steps Down After 9 Years
Chief Commerical Officer Luke Miels will replace outgoing GSK CEO Emma Walmsley at the U.K. pharma next year.
September 29, 2025
·
4 min read
·
Annalee Armstrong
Editorial
Novo’s CEO Doesn’t Seem To Mind Being Big Pharma’s Villian
Novo Nordisk, under new CEO Maziar Mike Doustdar, has a new attitude. It’s making Pfizer livid.
October 31, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
Ascendis Pharma Reports First Quarter 2025 Financial Results
May 1, 2025
·
11 min read
1 of 64,107
Next
